Thursday , May 13 2021

California research team, promising announcement Results for the Universal Peptide-Based Cancer Vaccine



California Santa Clara (PRNewswire / -) Dr. Ing. The California Rath Research Institute has developed a cancer vaccine that reduces tumor growth. This peptide-based vaccine targets specific enzymes called metalloproteinases (MMPs) that are involved in tumor growth, tumor metastasis and angiogenesis (angiogenesis). doctor. Rath and colleagues showed that mice vaccinated with peptides infected with melanoma cell lines that contained specific MMP-2 and MMP-9 sequences showed an average tumor reduction of about 76% compared to unvaccinated tumors. Surprisingly, animals vaccinated with some vaccines did not cause cancer at all.

The study was published in the online journal of cellular medicine and natural health in October 2018.

Cancer is still the second largest epidemic in the world. The disease kills 7 million people each year. This new treatment can dramatically change these statistics. Compared to monoclonal antibodies (Mabs) or biosimilar molecules that have recently been developed as anticancer drugs, the anti-MMP vaccine approach promises to be far more effective and inexpensive in the global fight against infectious diseases. While Mabs / biosimilars target certain types of cancer, anti-MMP vaccines can fight against all types of cancer. Another advantage is that unlike Mabs / Biosimilars generally need to be injected once or twice a month and the anti-MMP vaccine only needs to be injected once and should be vaccinated several years later.

Successful MMP vaccination can be provided to patients at a national or international medical facility at a reasonable cost.

To provide this valuable technology to patients and the majority of countries around the world at an affordable price, Rath has applied for patent protection in many countries. The institute seeks to develop promising technologies aimed at successfully treating, preempting, and ultimately eliminating cancer in public and government research institutions and other nonprofit organizations.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

U.S. Patent Nos. 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Contact and Contact:

Dr. Alexandra Niezwekey
CEO
Dr. Ras Institute
Email: Contact@drrath.com


Source link